Literature DB >> 31719727

β-d-Glucan and Aspergillus Galactomannan assays in the diagnosis of invasive fungal infections.

Mahadevan Kumar1, M Mugunthan2.   

Abstract

BACKGROUND: With an increase in the number of patients who are immunosuppressed or immunocompromised there has been an increase in invasive fungal infection (IFI) in the past few decades with its associated high morbidity and mortality, ranging from 60% to 90%. The critical problem is the identification of the causative fungus and initiation of appropriate therapy. Hence, there is a requirement for better diagnostic methods for IFI. Detection of markers for the presence of fungi during early stage of the infection, such as constituents of the cell wall or fungal DNA, is essential for timely diagnosis of IFI. Galactomannan (GM) which is a cell wall surface antigen is the most studied diagnostic marker, followed by 1,3 β-d-Glucan (BG) which is seen in deep layers of cell wall.
METHODS: We have assessed the effectiveness of Galactomannan/β-d-Glucan for the early diagnosis of IFI in immunosuppressed patients in our tertiary care setting.
RESULTS: The sensitivity, specificity, positive predictive value and negative predictive value of GM assay were 45%, 93%, 86% and 63% respectively, while the BG assay showed a sensitivity of 78%, specificity of 85%, Positive predictive value (PPV) 84% and Negative predictive value (NPV) 79%.
CONCLUSION: BG assay is better for detection of IFI in patients with immunosuppression. However, a combination of both BG and GM assays would be the best approach as BG assay is highly sensitive, while the GM assay is highly specific for diagnosing IFI.
© 2017 Published by Elsevier B.V. on behalf of Director General, Armed Forces Medical Services.

Entities:  

Keywords:  Antigen detection assays; Galactomannan; Invasive fungal infections; β-d-Glucan

Year:  2017        PMID: 31719727      PMCID: PMC6838501          DOI: 10.1016/j.mjafi.2017.10.005

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  28 in total

1.  Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: how much enhanced, how much earlier, and at what cost?

Authors:  Matthew E Falagas; Panayotis T Tassios
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

2.  Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System.

Authors:  R L Gorton; P L White; E Bagkeris; D Cotterall; R Desai; T McHugh; C C Kibbler
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

3.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

4.  Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan.

Authors:  Carmen Pazos; José Pontón; Amalia Del Palacio
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-glucan chromogenic assay in serum samples.

Authors:  J Acosta; M Catalan; A del Palacio-Peréz-Medel; D Lora; J-C Montejo; M-S Cuetara; M-D Moragues; J Ponton; A del Palacio
Journal:  Clin Microbiol Infect       Date:  2010-11-05       Impact factor: 8.067

6.  Measurement of (1-3)-beta-D-glucan derived from different gauze types.

Authors:  Hajime Kanamori; Keiji Kanemitsu; Tomomitsu Miyasaka; Koken Ameku; Shiro Endo; Tetsuji Aoyagi; Ken Inden; Masumitsu Hatta; Natsuo Yamamoto; Hiroyuki Kunishima; Hisakazu Yano; Koki Kaku; Yoichi Hirakata; Mitsuo Kaku
Journal:  Tohoku J Exp Med       Date:  2009-02       Impact factor: 1.848

7.  Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005.

Authors:  Konrad Donhuijsen; Peter Petersen; Werner Kurt Schmid
Journal:  Dtsch Arztebl Int       Date:  2008-07-14       Impact factor: 5.594

Review 8.  Infections with Aspergillus species.

Authors:  V T Andriole
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

9.  Invasive Aspergillus infections in allo-SCT recipients: environmental sampling, nasal and oral colonization and galactomannan testing.

Authors:  A Nihtinen; V-J Anttila; M Richardson; T Ruutu; E Juvonen; T Meri; L Volin
Journal:  Bone Marrow Transplant       Date:  2009-07-20       Impact factor: 5.483

10.  Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients.

Authors:  R Y Hachem; D P Kontoyiannis; R F Chemaly; Y Jiang; R Reitzel; I Raad
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

View more
  2 in total

1.  The burden of serious fungal infections in Azerbaijan.

Authors:  Ravil M Huseynov; Samir S Javadov; Ali Osmanov; Shahin Khasiyev; Samira R Valiyeva; Esmira Almammadova; David W Denning
Journal:  Ther Adv Infect Dis       Date:  2021-09-03

2.  (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

Authors:  Sandra K White; Robert L Schmidt; Brandon S Walker; Kimberly E Hanson
Journal:  Cochrane Database Syst Rev       Date:  2020-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.